Open Access

Oral administration of Lactobacillus plantarum 06CC2 prevents experimental colitis in mice via an anti‑inflammatory response

  • Authors:
    • Akihito Tanaka
    • Shuji Kanmura
    • Yuko Morinaga
    • Katsuto Kawabata
    • Shiho Arima
    • Fumisato Sasaki
    • Yuichirou Nasu
    • Shiroh Tanoue
    • Shinichi Hashimoto
    • Masahiko Takeshita
    • Shiro Takeda
    • Akio Ido
  • View Affiliations

  • Published online on: January 9, 2020     https://doi.org/10.3892/mmr.2020.10925
  • Pages: 1181-1191
  • Copyright: © Tanaka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Dysbiosis of the enteric microbiota causes gastrointestinal diseases, including colitis. The present study investigated the beneficial effect of Lactobacillus plantarum 06CC2 in experimental colitis in mice. An experimental colitis model in C57BL6 mice was induced using dextran sulfate sodium. Mice were orally administered 06CC2 (06CC2 group) or PBS only (control group) by gavage. The disease activity index (DAI), histological grading, and colon tissue and colonic lamina propria mononuclear cells (LPMCs) were examined macroscopically and histopathologically, and the expression levels of inflammation‑associated cytokines (IL‑6, IL‑12, TNF‑α and IL‑10) in these samples were determined. Compared with the control group, the 06CC2 group exhibited a significantly lower DAI (1.5±0.8 vs. 0.2±0.3, respectively; P<0.05) and pathology score (6.3±1.5 vs. 3.8±1.3, respectively; P<0.05). IL‑10 expression in colonic LPMCs was higher in the 06CC2 group than in the control group, although there was no significant difference in IFN‑γ, IL‑6 or IL‑12 expression in colonic LPMCs between the two groups. In addition, 06CC2 stimulated the production of IL‑10 from CD11b‑positive cells and CD11c‑positive cells in the colon. The 06CC2 strain induced IL‑10 production in the colon and attenuated colon inflammation.
View Figures
View References

Related Articles

Journal Cover

March-2020
Volume 21 Issue 3

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tanaka A, Kanmura S, Morinaga Y, Kawabata K, Arima S, Sasaki F, Nasu Y, Tanoue S, Hashimoto S, Takeshita M, Takeshita M, et al: Oral administration of Lactobacillus plantarum 06CC2 prevents experimental colitis in mice via an anti‑inflammatory response. Mol Med Rep 21: 1181-1191, 2020
APA
Tanaka, A., Kanmura, S., Morinaga, Y., Kawabata, K., Arima, S., Sasaki, F. ... Ido, A. (2020). Oral administration of Lactobacillus plantarum 06CC2 prevents experimental colitis in mice via an anti‑inflammatory response. Molecular Medicine Reports, 21, 1181-1191. https://doi.org/10.3892/mmr.2020.10925
MLA
Tanaka, A., Kanmura, S., Morinaga, Y., Kawabata, K., Arima, S., Sasaki, F., Nasu, Y., Tanoue, S., Hashimoto, S., Takeshita, M., Takeda, S., Ido, A."Oral administration of Lactobacillus plantarum 06CC2 prevents experimental colitis in mice via an anti‑inflammatory response". Molecular Medicine Reports 21.3 (2020): 1181-1191.
Chicago
Tanaka, A., Kanmura, S., Morinaga, Y., Kawabata, K., Arima, S., Sasaki, F., Nasu, Y., Tanoue, S., Hashimoto, S., Takeshita, M., Takeda, S., Ido, A."Oral administration of Lactobacillus plantarum 06CC2 prevents experimental colitis in mice via an anti‑inflammatory response". Molecular Medicine Reports 21, no. 3 (2020): 1181-1191. https://doi.org/10.3892/mmr.2020.10925